Skip Nav Destination
Issues
1 April 2016
-
Cover Image
Cover Image
The cover depicts in vitro coculture of patient-derived tumor-associated stroma (TAS) and pancreatic cancer (PC) cells. Immunofluorescent staining demonstrates cells fixed and stained with phalloidin (green) and DAPI (blue), outlining actin cytoskeletal networks between TAS and PC cells. For details, see the article by Delitto and colleagues on page 1787 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Perspectives in Regulatory Science and Policy
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms
Paul G. Kluetz; Ashley Slagle; Elektra J. Papadopoulos; Laura Lee Johnson; Martha Donoghue; Virginia E. Kwitkowski; Wen-Hung Chen; Rajeshwari Sridhara; Ann T. Farrell; Patricia Keegan; Geoffrey Kim; Richard Pazdur
Molecular Pathways
Review
Cancer Therapy: Clinical
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
Carsten U. Niemann; Sarah E.M. Herman; Irina Maric; Julio Gomez-Rodriguez; Angelique Biancotto; Betty Y. Chang; Sabrina Martyr; Maryalice Stetler-Stevenson; Constance M. Yuan; Katherine R. Calvo; Raul C. Braylan; Janet Valdez; Yuh Shan Lee; Deanna H. Wong; Jade Jones; Clare Sun; Gerald E. Marti; Mohammed Z.H. Farooqui; Adrian Wiestner
Author Choice
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Cynthia X. Ma; Jingqin Luo; Michael Naughton; Foluso Ademuyiwa; Rama Suresh; Malachi Griffith; Obi L. Griffith; Zachary L. Skidmore; Nicholas C. Spies; Avinash Ramu; Lee Trani; Timothy Pluard; Gayathri Nagaraj; Shana Thomas; Zhanfang Guo; Jeremy Hoog; Jing Han; Elaine Mardis; Craig Lockhart; Matthew J. Ellis
Personalized Medicine and Imaging
Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Clemens Krepler; Min Xiao; Katrin Sproesser; Patricia A. Brafford; Batool Shannan; Marilda Beqiri; Qin Liu; Wei Xu; Bradley Garman; Katherine L. Nathanson; Xiaowei Xu; Giorgos C. Karakousis; Gordon B. Mills; Yiling Lu; Tamer A. Ahmed; Poulikos I. Poulikakos; Giordano Caponigro; Markus Boehm; Malte Peters; Lynn M. Schuchter; Ashani T. Weeraratna; Meenhard Herlyn
Author Choice
The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy
Chenchen Wang; Weijian Guo; Min Zhou; Xiaodong Zhu; Dongmei Ji; Wenhua Li; Xin Liu; Zhonghua Tao; Xiaowei Zhang; Yingjian Zhang; Jin Li
Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy
Siu W. Lam; the ATX trial team; Nienke M. Nota; the ATX trial team; Agnes Jager; the ATX trial team; Monique M.E.M. Bos; the ATX trial team; Joan van den Bosch; the ATX trial team; Ankie M.T. van der Velden; the ATX trial team; Johanneke E.A. Portielje; the ATX trial team; Aafke H. Honkoop; the ATX trial team; Harm van Tinteren; the ATX trial team; Epie Boven; the ATX trial team
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
Ovidiu C. Andronesi; Franziska Loebel; Wolfgang Bogner; Małgorzata Marjańska; Matthew G. Vander Heiden; A. John Iafrate; Jorg Dietrich; Tracy T. Batchelor; Elizabeth R. Gerstner; William G. Kaelin; Andrew S. Chi; Bruce R. Rosen; Daniel P. Cahill
ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment
Laetitia E. Lamberts; Catharina W. Menke-van der Houven van Oordt; Eva J. ter Weele; Frederike Bensch; Michiel M. Smeenk; Johannes Voortman; Otto S. Hoekstra; Simon P. Williams; Bernard M. Fine; Daniel Maslyar; Johan R. de Jong; Jourik A. Gietema; Carolien P. Schröder; Alphons H.H. Bongaerts; Marjolijn N. Lub-de Hooge; Henk M.W. Verheul; Sandra M. Sanabria Bohorquez; Andor W.J.M. Glaudemans; Elisabeth G.E. de Vries
Cancer Therapy: Preclinical
Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer
Renata Ferrarotto; Ruchitha Goonatilake; Suk Young Yoo; Pan Tong; Uma Giri; Shaohua Peng; John Minna; Luc Girard; Yuehong Wang; Liguang Wang; Lerong Li; Lixia Diao; David H. Peng; Don L. Gibbons; Bonnie S. Glisson; John V. Heymach; Jing Wang; Lauren A. Byers; Faye M. Johnson
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
Juliana Benito; Marc S. Ramirez; Niki Zacharias Millward; Juliana Velez; Karine G. Harutyunyan; Hongbo Lu; Yue-xi Shi; Polina Matre; Rodrigo Jacamo; Helen Ma; Sergej Konoplev; Teresa McQueen; Andrei Volgin; Marina Protopopova; Hong Mu; Jaehyuk Lee; Pratip K. Bhattacharya; Joseph R. Marszalek; R. Eric Davis; James A. Bankson; Jorge E. Cortes; Charles P. Hart; Michael Andreeff; Marina Konopleva
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer
Wei Mo; Qingxin Liu; Curtis Chun-Jen Lin; Hui Dai; Yang Peng; Yulong Liang; Guang Peng; Funda Meric-Bernstam; Gordon B. Mills; Kaiyi Li; Shiaw-Yih Lin
Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer
Yu Kang; Archana S. Nagaraja; Guillermo N. Armaiz-Pena; Piotr L. Dorniak; Wei Hu; Rajesha Rupaimoole; Tao Liu; Kshipra M. Gharpure; Rebecca A. Previs; Jean M. Hansen; Cristian Rodriguez-Aguayo; Cristina Ivan; Prahlad Ram; Vasudha Sehgal; Gabriel Lopez-Berestein; Susan K. Lutgendorf; Steven W. Cole; Anil K. Sood
Biology of Human Tumors
Author Choice
Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Claire Jenkinson; Victoria L. Elliott; Anthony Evans; Lucy Oldfield; Rosalind E. Jenkins; Darragh P. O'Brien; Sophia Apostolidou; Aleksandra Gentry-Maharaj; Evangelia-O Fourkala; Ian J. Jacobs; Usha Menon; Trevor Cox; Fiona Campbell; Stephen P. Pereira; David A. Tuveson; B. Kevin Park; William Greenhalf; Robert Sutton; John F. Timms; John P. Neoptolemos; Eithne Costello
Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer
Yijun Yang; Dingwu Jia; Hogyoung Kim; Zakaria Y. Abd Elmageed; Amrita Datta; Rodney Davis; Sudesh Srivastav; Krzysztof Moroz; Byron E. Crawford; Krishnarao Moparty; Raju Thomas; Robert S. Hudson; Stefan Ambs; Asim B. Abdel-Mageed
Identification of Developmental Endothelial Locus-1 on Circulating Extracellular Vesicles as a Novel Biomarker for Early Breast Cancer Detection
Pyong-Gon Moon; Jeong-Eun Lee; Young-Eun Cho; Soo Jung Lee; Jin Hyang Jung; Yee Soo Chae; Han-Ik Bae; Young-Bum Kim; In-San Kim; Ho Yong Park; Moon-Chang Baek
The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer
Shuang G. Zhao; Joseph R. Evans; Vishal Kothari; Grace Sun; Ashley Larm; Victor Mondine; Edward M. Schaeffer; Ashley E. Ross; Eric A. Klein; Robert B. Den; Adam P. Dicker; R. Jeffrey Karnes; Nicholas Erho; Paul L. Nguyen; Elai Davicioni; Felix Y. Feng
Author Choice
Nicotine Reduces Survival via Augmentation of Paracrine HGF–MET Signaling in the Pancreatic Cancer Microenvironment
Daniel Delitto; Dongyu Zhang; Song Han; Brian S. Black; Andrea E. Knowlton; Adrian C. Vlada; George A. Sarosi; Kevin E. Behrns; Ryan M. Thomas; Xiaomin Lu; Chen Liu; Thomas J. George; Steven J. Hughes; Shannon M. Wallet; Jose G. Trevino
Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients
Devbarna Sinha; for the Australian Ovarian Cancer Study Group; Lynn Chong; for the Australian Ovarian Cancer Study Group; Joshy George; for the Australian Ovarian Cancer Study Group; Holger Schlüter; for the Australian Ovarian Cancer Study Group; Susann Mönchgesang; for the Australian Ovarian Cancer Study Group; Stuart Mills; for the Australian Ovarian Cancer Study Group; Jason Li; for the Australian Ovarian Cancer Study Group; Christopher Parish; for the Australian Ovarian Cancer Study Group; David Bowtell; for the Australian Ovarian Cancer Study Group; Pritinder Kaur; for the Australian Ovarian Cancer Study Group
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.